Compare Pfizer with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs STRIDES PHARMA SCIENCE - Comparison Results

PFIZER     Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER STRIDES PHARMA SCIENCE PFIZER/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x 32.7 14.5 224.9% View Chart
P/BV x 5.5 0.9 638.3% View Chart
Dividend Yield % 0.6 0.6 109.9%  

Financials

 PFIZER   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    PFIZER
Mar-18
STRIDES PHARMA SCIENCE
Mar-18
PFIZER/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs2,3651,147 206.2%   
Low Rs1,625642 253.1%   
Sales per share (Unadj.) Rs430.3317.2 135.6%  
Earnings per share (Unadj.) Rs78.77.8 1,003.3%  
Cash flow per share (Unadj.) Rs93.225.1 371.9%  
Dividends per share (Unadj.) Rs20.002.00 1,000.0%  
Dividend yield (eoy) %1.00.2 448.4%  
Book value per share (Unadj.) Rs586.5274.3 213.9%  
Shares outstanding (eoy) m45.7589.50 51.1%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.62.8 164.4%   
Avg P/E ratio x25.3114.0 22.2%  
P/CF ratio (eoy) x21.435.7 60.0%  
Price / Book Value ratio x3.43.3 104.3%  
Dividend payout %25.425.5 99.7%   
Avg Mkt Cap Rs m91,27180,058 114.0%   
No. of employees `0002.62.5 104.9%   
Total wages/salary Rs m3,1434,341 72.4%   
Avg. sales/employee Rs Th7,484.811,325.8 66.1%   
Avg. wages/employee Rs Th1,195.01,731.4 69.0%   
Avg. net profit/employee Rs Th1,369.1280.1 488.9%   
INCOME DATA
Net Sales Rs m19,68528,394 69.3%  
Other income Rs m1,143941 121.5%   
Total revenues Rs m20,82829,334 71.0%   
Gross profit Rs m5,0033,965 126.2%  
Depreciation Rs m6631,540 43.0%   
Interest Rs m41,962 0.2%   
Profit before tax Rs m5,4791,403 390.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-168 0.0%   
Extraordinary Inc (Exp) Rs m0-436 0.0%   
Tax Rs m1,87897 1,930.5%   
Profit after tax Rs m3,601702 512.8%  
Gross profit margin %25.414.0 182.0%  
Effective tax rate %34.36.9 494.4%   
Net profit margin %18.32.5 739.7%  
BALANCE SHEET DATA
Current assets Rs m24,16724,836 97.3%   
Current liabilities Rs m9,54418,993 50.3%   
Net working cap to sales %74.320.6 361.0%  
Current ratio x2.51.3 193.6%  
Inventory Days Days5571 77.6%  
Debtors Days Days29113 25.3%  
Net fixed assets Rs m9,51434,289 27.7%   
Share capital Rs m458895 51.1%   
"Free" reserves Rs m26,37523,651 111.5%   
Net worth Rs m26,83224,546 109.3%   
Long term debt Rs m2515,513 0.2%   
Total assets Rs m36,90065,437 56.4%  
Interest coverage x1,305.51.7 76,123.3%   
Debt to equity ratio x00.6 0.1%  
Sales to assets ratio x0.50.4 122.9%   
Return on assets %9.84.1 239.9%  
Return on equity %13.42.9 469.1%  
Return on capital %20.46.9 296.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m2215,697 0.1%   
Fx outflow Rs m1,489735 202.4%   
Net fx Rs m-1,46614,962 -9.8%   
CASH FLOW
From Operations Rs m3,3181,871 177.4%  
From Investments Rs m-2,3835,826 -40.9%  
From Financial Activity Rs m-1,104-10,157 10.9%  
Net Cashflow Rs m-169-2,615 6.4%  

Share Holding

Indian Promoters % 0.0 27.7 -  
Foreign collaborators % 63.9 0.0 -  
Indian inst/Mut Fund % 7.5 37.8 19.8%  
FIIs % 4.9 8.6 57.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.7 25.9 91.5%  
Shareholders   85,207 56,241 151.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   SUVEN LIFESCIENCES  SHASUN PHARMA  SANOFI INDIA  TTK HEALTHCARE  SUN PHARMA  

Compare PFIZER With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

PFIZER Announces Quarterly Results (1QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PFIZER has posted a net profit of Rs 1 bn (up 22.8% YoY). Sales on the other hand came in at Rs 5 bn (up 6.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

PFIZER Announces Quarterly Results (4QFY19); Net Profit Up 4.7% (Quarterly Result Update)

May 29, 2019 | Updated on May 29, 2019

For the quarter ended March 2019, PFIZER has posted a net profit of Rs 1 bn (up 4.7% YoY). Sales on the other hand came in at Rs 5 bn (up 3.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY19); Net Profit Down 27.5% (Quarterly Result Update)

Jan 30, 2019 | Updated on Jan 30, 2019

For the quarter ended December 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 316 m (down 27.5% YoY). Sales on the other hand came in at Rs 8 bn (up 6.1% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Oct 18, 2019 (Close)

TRACK PFIZER

PFIZER - ALKEM LABORATORIES COMPARISON

COMPARE PFIZER WITH

MARKET STATS